Differential Sensitivity of Human Kinases VRK1 and VRK2 to Inhibitors
Author Information
Author(s): Marta Vázquez-Cedeira, Iria Barcia-Sanjurjo, Marta Sanz-García, Ramiro Barcia, Pedro A. Lazo
Primary Institution: Instituto de Biología Molecular y Celular del Cáncer, CSIC-Universidad de Salamanca
Hypothesis
Do VRK1 and VRK2 have different sensitivities to kinase inhibitors?
Conclusion
VRK1 and VRK2 exhibit distinct patterns of sensitivity to various kinase inhibitors, which could inform the development of specific inhibitors for clinical use.
Supporting Evidence
- VRK1 is more sensitive to staurosporine and RO 31–8220, while VRK2 is more sensitive to Cdk1 inhibitor and roscovitine.
- Both VRK proteins are poorly inhibited by a wide range of kinase inhibitors.
- VRK1 identifies a subgroup of breast cancer with a poorer prognosis.
Takeaway
This study found that two proteins, VRK1 and VRK2, respond differently to certain drugs, which could help create better treatments for cancer.
Methodology
The study involved testing the sensitivity of VRK1 and VRK2 to a panel of kinase inhibitors using in vitro kinase assays.
Limitations
The inhibitors tested were not effective at low concentrations, making them unsuitable for in vivo use.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website